CD38 and B-cell non-Hodgkin lymphoma: Armed with these compelling data, we meticulously crafted our study to investigate the potential influence of heightened CD38 expression and extracellular ADO production on various demographic, clinical, and hematological parameters in mature B-cell lymphoma patients, including CLL and B-NHL.